Selected References:
- Aronne LJ. 1998. Obesity. Womens Health Issues 82(1):161- 181.
- Chang JJ, Lathi RB, Kim SH. 2020. A retrospective study examining phentermine on preconception weight loss and pregnancy outcomes. Endocrine Practice;26(9):990-996. https://doi.org/10.4158/EP-2019-0609
- Food and Drug Administration. 2012. Prescribing information for ADIPEX-P®. Retrieved April 2024 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf
- Food and Drug Administration. 2013. Prescribing information for SUPRENZA Retrieved April 2024 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202088s005lbl.pdf.
- Food and Drug Administration. 2023. Prescribing information for Qsymia®. Retrieved April 2024 from https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf.
- Hale TW. 2008. Medications and Mothers’ Milk, 13th ed. Amarillo, TX: Hale Publishing.
- Johnson KA, et al. 1998. Pregnancy outcome of women exposed to Fen/Phen [abstract]. Organization of Teratology Information Specialists Annual Meeting, June 1998.
- Jones KL, et al. 2002. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. Teratology 65:125-130.
- No authors listed. 2013. Topiramate + phentermine. An excessively dangerous appetite-suppressant combination. Prescrire Int 22(136):61-4.
- Robert E, et al. 1995. Neural tube defects and maternal weight reduction in early pregnancy. Reprod Toxicol 9(1):57-59.
- Silverstone, T. 1982. Drugs and Appetite. New York: Academic Press.
- Stein AD, et al. 1995. Third-trimester pregnancy weight gain and intrauterine growth: The Dutch Famine Birth Cohort Study. Hum Biol 67(1):135-150.
- Winick M. 1989. Nutrition, Pregnancy, and Early Infancy. Baltimore: Williams & Wilkins.
